Jainson Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 11-07-2024
- Paid Up Capital ₹ 0.20 M
as on 11-07-2024
- Company Age 28 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.10 M
as on 11-07-2024
- Revenue 2.31%
(FY 2020)
- Profit 39.45%
(FY 2020)
- Ebitda -140.09%
(FY 2020)
- Net Worth -25.03%
(FY 2020)
- Total Assets -13.53%
(FY 2020)
About Jainson Pharmaceuticals
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.20 M.
The company currently has active open charges totaling ₹5.10 M.
Yogesh Patni and Nemichand Patni serve as directors at the Company.
- CIN/LLPIN
U24230MH1996PTC100729
- Company No.
100729
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Jul 1996
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Jainson Pharmaceuticals Private Limited offer?
Jainson Pharmaceuticals Private Limited offers a wide range of products and services, including Ubtan Powder, Natural Cosmetics, Multani Mitti, Hair Shampoo, Ayurvedic Shampoo, Herbal Powder, Neem Powder, Amla Powder, Reetha Powder, Ayurvedic Powder and Medicinal Herbs.
Who are the key members and board of directors at Jainson Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nemichand Patni  | Director | 01-Jul-1996 | Current |
| Yogesh Patni | Director | 06-May-2008 | Current |
Financial Performance of Jainson Pharmaceuticals.
Jainson Pharmaceuticals Private Limited, for the financial year ended 2020, experienced modest growth in revenue, with a 2.31% increase. The company also saw a substantial improvement in profitability, with a 39.45% increase in profit. The company's net worth observed a substantial decline by a decrease of 25.03%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jainson Pharmaceuticals?
In 2020, Jainson Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 29 Sep 2017 | ₹4.60 M | Open |
Abhyudaya Co-Op. Bank Ltd. Creation Date: 16 Sep 2009 | ₹0.50 M | Open |
How Many Employees Work at Jainson Pharmaceuticals?
Unlock and access historical data on people associated with Jainson Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jainson Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jainson Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
